Collectively, our clinical and experimental data establish MELK as a critical oncogenic driver in ccRCC, whose overexpression correlates with advanced tumor progression, poor prognosis, and enhanced malignant phenotypes, while its knockdown potently suppresses tumor aggressiveness, highlighting its potential as both a prognostic biomarker and therapeutic target. Here, MELK is linked to neoplasm.